[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622976":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":119,"collaborators":10,"id":121,"slug":122,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":10,"eligibilityCriteria":127,"healthyVolunteers":123,"sex":128,"minAge":129,"maxAge":10,"enrollmentInfo":130,"targetDuration":10,"studyType":133,"phases":10,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants With Urothelial Carcinoma",null,"Participants will have histological or cytologically confirmed urothelial carcinoma",[13,14],"Other: Non-therapeutic Nerve Conduction Studies","Other: Non-therapeutic assessment of patient-reported neuropathy",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"Non-therapeutic Nerve Conduction Studies","Non-invasive nerve conduction studies (NCS) offer an objective, quantitative approach to assess peripheral nerve function, particularly in sensory fibers, which are most commonly affected in chemotherapy-induced peripheral neuropathy\u002FCIPN",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Non-therapeutic assessment of patient-reported neuropathy","To evaluate the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in participants receiving enfortumab vedotin, we will collect non-therapeutic, participant-reported outcomes",[9],[25],{"name":26,"affiliation":5,"role":27},"Samuel Funt, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","646-888-4770","funts@mskcc.org",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":10},"Gopakumar Iyer, MD","646-888-4717",[37,53,64,75,87,98,108],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-74.54932,40.70621,{"lat":49,"lon":48},[52],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":54,"status":39,"city":55,"state":41,"zip":56,"country":43,"countryCode":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":46,"coordinates":58},[59,60],-74.11709,40.39428,{"lat":60,"lon":59},[63],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":65,"status":39,"city":66,"state":41,"zip":67,"country":43,"countryCode":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":46,"coordinates":69},[70,71],-74.02292,41.04676,{"lat":71,"lon":70},[74],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":76,"status":39,"city":77,"state":78,"zip":79,"country":43,"countryCode":44,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":46,"coordinates":81},[82,83],-73.29289,40.84288,{"lat":83,"lon":82},[86],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":88,"status":39,"city":89,"state":78,"zip":90,"country":43,"countryCode":44,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":46,"coordinates":92},[93,94],-73.71263,40.96899,{"lat":94,"lon":93},[97],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":99,"status":39,"city":78,"state":78,"zip":100,"country":43,"countryCode":44,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Memorial Sloan Kettering Cancer Center (All Protocol Activites)","10065",{"type":46,"coordinates":102},[103,104],-74.00597,40.71427,{"lat":104,"lon":103},[107],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":109,"status":39,"city":110,"state":78,"zip":111,"country":43,"countryCode":44,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Memorial Sloan Kettering Nassau (Limited Protocol Activites)","Rockville Centre","11553",{"type":46,"coordinates":113},[114,115],-73.64124,40.65871,{"lat":115,"lon":114},[118],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"type":120,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622976","a-study-of-neuropathy-caused-by-enfortumab-vedotin-in-people-with-urothelial-carcinoma-100622976",false,"NCT07390617","A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma","Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin","Inclusion Criteria:\n\n* Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.\n* Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of ≤ 3 within 28 days prior to consent.\n* Histological or cytologically confirmed urothelial carcinoma.\n* Patients must be planned to start systemic therapy with enfortumab vedotin\n* At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab\n\nExclusion Criteria:\n\nSubjects meeting any of the criteria below may not participate in the study:\n\n* Inability of the subject to understand and comply with study procedures.\n* Having previously received enfortumab vedotin\n* Students\u002Femployees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).","ALL","18 Years",{"count":131,"type":132},50,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)",[136,137,138],"Neuropathy","Urothelial Carcinoma","Metastatic Urothelial Carcinoma",[140,141,142,5,143],"urothelial carcinoma","metastatic urothelial carcinoma","neuropathy","25-371","2026-05-26",{"date":146,"type":147},"2026-05-29","ACTUAL",{"date":149,"type":147},"2026-01-20",{"date":151,"type":132},"2028-01-20",{"name":5,"class":6},7]